Wed, Apr 16, 2014, 2:07 PM EDT - U.S. Markets close in 1 hr 53 mins

Recent

% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

sigma_capitals 5 posts  |  Last Activity: Apr 13, 2014 9:39 PM Member since: Jan 25, 2005
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    CEO's presentation on 4/9

    by sigma_capitals Apr 11, 2014 7:38 PM
    sigma_capitals sigma_capitals Apr 13, 2014 9:39 PM Flag

    hmm... Yahoo say 8 responses and yet I opened this link and only one shows up! Is there some sort of filter I need to fix?

  • Reply to

    CEO's presentation on 4/9

    by sigma_capitals Apr 11, 2014 7:38 PM
    sigma_capitals sigma_capitals Apr 11, 2014 11:25 PM Flag

    Ok. Thanks. He did say more patients on the placebo arm tested culture negative after the 84 day period. I wasn't aware those additional patients were first monitored for 6 months and consistently failed to be cured until they were then put on Arikayce.

    What I don't know for sure is if the remaining patients that are yet to convert to culture negative during the first 84 days will remain on Arikayce for additional 84 days (total of 168) before reporting the next set of results. And if that's the case, I would expect the data to be presented in 3 month, which is late June, not May.

    Thank you.

  • sigma_capitals by sigma_capitals Apr 11, 2014 7:38 PM Flag

    I carefully listened to the CEO's presentation and rewinded some segments a number of times to make sure I clearly understood what he said. One of his statements got my attention. Feel free to respond and confirm if I understood the following correctly:

    1. Did he say that patients will continue to be on Arikayce for another 84 (for a today of 168 days) and additional patients (besides the 11) have already demonstrated culture conversion to negative (i.e., cured)?

    2. If so, since the reduction in bacterial density was "numerically superior, not statistically significant", isn't there a chance with the continued study that statistical significance could be attained if the trending in reduction of bacterial density continues among patients?

    Thank you.

  • His continued negativity against INSM was brushed off yet again.

    This time he was WRONG on MNKD. Ever gushing with ignorance, he kept trashing MNDK's leading drug candidate up until close of business today. Then after the close, FDA Advisory Committee overwhelmingly recommended Approval of MNKD's drug Afrezza not only for Type I diabetes, but for Type II as well.

    Adam Feuerstein has no education or any working experience in any scientific discipline whatsoever. Yet, he pretends to understand the science behind drug developments and clinical trails, while continuing to spew utter garbage. Says a lot about his employer: The Street. I'd hate to be one of those that believed him and lost their fortunes.

  • "delusion er"?! I take it English is not your first language. The desperation you continue to exhibit on this message board is pitiful, yet amusing to watch. Good luck to you.

INSM
12.58+0.010(+0.08%)2:06 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.